Andere talen Hubei Biocause Pharmaceutical Co., Ltd.

Aandelen

000627

CNE000000F48

slotkoers Shenzhen S.E. Andere beurzen 00:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,35 ^CNY	+4,91%		+2,62%	-17,25%

15/04	Hubei Biocause Pharmaceutical Co, Ltd. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
15/01	Biocause Pharma's verzekeringseenheid boekt stabiele jaarlijkse premie in 2023	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023	15/01
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30-10-23
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.	22-09-23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30-08-23
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period	14-08-23
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period	12-06-23
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023	22-05-23
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income	16-05-23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27-04-23
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022	24-04-23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14-04-23
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%	30-12-22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28-10-22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29-08-22
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake	20-06-22
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022	24-05-22
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	05-05-22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29-04-22
Hubei Biocause’s Pharmaceutical Ingredients Unit Surges 64% in Shenzhen Debut	22-12-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hubei Biocause Pharmaceutical Co., Ltd.

Aandelen

000627

CNE000000F48

Andere talen

Filters